Dr. Ron Milo recommends the Autoimmunity Congress to Neurologists.
"The central nervous system (CNS) is no longer considered to be an "immune privileged" site. All arms of the immune system may interact with all levels and tissues of the nervous systems in health and disease to generate Immune mediated disorders that span the whole neuroaxis, including the CNS, peripheral nerves, neuromuscular junction and muscles. Indeed, most of the "true" autoimmune diseases fulfilling Witebsky's criteria involve the nervous system, especially the neuromuscular junction (e.g. myasthenia gravis, Lambert-Eaton myasthenic syndrome), and several encephalopathies, channelopathies, epilepsies, paraneoplastic syndromes and other conditions are emerging as autoimmune neurological disorders.
In the upcoming Congress on Autoimmunity in Leipzig, neurologists will have the opportunity to learn about some of the most recent advances made in this exiting field of neuroimmunology, to get insight into new mechanisms, target antigens, biomarkers and therapies of neurological autoimmune diseases and to discuss whether their spectrum is expanding to involve additional conditions such as Rett syndrome and psychosis.
The central role of B-cells in the pathogenesis of multiple sclerosis (MS), once believed to be a T-cell mediated autoimmune disease of the CNS, and the recent evidence for high efficacy of B-cell targeted immunotherapy in MS will be highlighted by Amit Bar-Or from Canada and Ron Milo from Israel in a session dedicated to "Autoimmune pathways in multiple sclerosis, myasthenia gravis and the central nervous system". In addition, the expanding spectrum of autoimmune encephalopathies and their specific antibodies will be presented by Josef Dalmau from Spain and Maarten Titulaer from the Netherlands. New insights into the role of T- and B-cell subsets in MS development and new mechanisms of MS therapies will be presented by others, as well as the effects of repeated infections on autoimmune Th17 cells and blood-brain barrier integrity. Finally, annexins as new players in autoimmunity and the involvement of the nervous system in systemic autoimmune diseases will be discussed.
This congress will, undoubtedly, provide participants with new insights and satisfy any neurologist interested in the rapidly expanding field of neuroimmunology."
View the session on Autoimmune pathways in MS, MG and the central nervous system.pdf
View the session on Autoimmune aspects of neurological diseases.pdf
Ron Milo, MD
Ron Milo is Chairman of the Department of Neurology and Director of the Multiple Sclerosis Center at the Barzilai Medical Center in Ashkelon at the Ben-Gurion University of the Negev, Israel.
Dr Milo obtained his medical degree from the Hebrew University Hadassah Medical School, Jerusalem. He completed his training in neurology at the Assaf Harofeh Medical Center, Tel Aviv University, and a Research Fellowship in neuroimmunology at the University of Maryland, Baltimore in MD, USA, where he studied the immunomodulatory properties of interferon-beta and glatiramer acetate in MS. Since his return to Israel in 1994, he has been involved in basic and clinical research in MS, and has accumulated more than 20 years of experience in conducting clinical trials in MS and other neurological fields.
Dr Milo has authored more than 250 papers, reviews and abstracts and is extensively involved in teaching neurology and neuroimmunology to medical students, residents and neurologists nationally and internationally, and has received several teaching awards.
Dr Milo's scientific and clinical interests include the immunology of MS, new therapies in MS, and immunomodulation, cognitive dysfunction and the conduction of clinical trials in MS. He is the Secretary of the Israel Society of Neuroimmunology and serves on the boards of the Israel Neurological Association and the Israel MS Society. He is also a member of the American Academy of Neurology (AAN), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) council, and the Scientific Panel on MS of the European Academy of Neurology (EAN).